{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:24:40Z","timestamp":1791869080563,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["109092"],"award-info":[{"award-number":["109092"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To assess late toxicity, quality of life and oncological outcome after consolidative whole abdominal radiotherapy (WART) following cytoreductive surgery and carboplatin\/paclitaxel chemotherapy in high risk patients with advanced ovarian cancer FIGO stage III using IMRT (Intensity modulated radiation therapy).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The OVAR-IMRT-02 study is a multi-center single-arm phase-II-trial. Twenty patients with optimally debulked ovarian cancer stage FIGO III with complete remission after chemotherapy were treated with intensity modulated WART. A total dose of 30\u2009Gy in 20 fractions was applied to the entire peritoneal cavity. Primary endpoint was treatment tolerability; secondary objectives were acute and chronic toxicities, quality of life, rates of therapy disruption\/abortion, progression-free survival (PFS) and overall survival (OS).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All patients completed treatment and 10\/20 patients (50%) reached the final study follow-up of 36\u2009months. Late side effects consisted of \u00b01-\u00b02 lower limb edema (44.5%), with one patient (5.6%) showing \u00b03 edema. Three patients (16.7%) showed elevated gamma-Glutamyltransferase. There were no severe late side effects regarding renal or hepatic function or any gastrointestinal toxicity greater than \u00b02. During WART, mean global health status decreased by 18.1 points (95%-CI: 7.1\u201329.0), but completely normalized after 6\u2009months. The same trend was observed for the function scale scores. Kaplan-Meier-estimated 1-, 2- and 3-year PFS was 74, 51 and 40%, respectively. 1-, 2- and 3-year OS was 89, 83 and 83%, respectively.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Intensity modulated WART after aggressive surgery and carboplatin\/paclitaxel chemotherapy is associated with an acceptable risk of acute and late toxicity and minor impact on long-term quality of life. Together with the promising results for PFS and OS, intensity modulated WART could offer a new therapeutic option for consolidation treatment of patients with advanced ovarian cancer.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The study is registered with ClinicalTrials.gov (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01180504?term=NCT01180504&amp;rank=1\">NCT01180504<\/jats:ext-link>). Registered 12 August 2010 \u2013 retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-019-1381-2","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T12:49:47Z","timestamp":1571662187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-5404","authenticated-orcid":false,"given":"Nathalie","family":"Arians","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinhard","family":"Kieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rochet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Herfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Lindel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"1381_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1381_CR2","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1001\/jama.291.22.2755","volume":"291","author":"MB Daly","year":"2004","unstructured":"Daly MB, Ozols RF. Symptoms of ovarian cancer--where to set the bar? JAMA. 2004;291:2755\u20136.","journal-title":"JAMA"},{"key":"1381_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-540-37696-5_9","volume":"174","author":"RC Bast","year":"2007","unstructured":"Bast RC, Brewer M, Zou C, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res. 2007;174:91\u2013100.","journal-title":"Recent Results Cancer Res"},{"key":"1381_CR4","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.2147\/DDDT.S124447","volume":"12","author":"D Lorusso","year":"2018","unstructured":"Lorusso D, Tripodi E, Maltese G, et al. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Des Devel Ther. 2018;12:1501\u20139.","journal-title":"Drug Des Devel Ther"},{"key":"1381_CR5","first-page":"34","volume":"26","author":"RF Ozols","year":"1999","unstructured":"Ozols RF. Chemotherapy for ovarian cancer. Semin Oncol. 1999;26:34\u201340.","journal-title":"Semin Oncol"},{"key":"1381_CR6","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A, L\u00fcck H-J, Meier W, et al. A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"1381_CR7","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/bjc.1998.710","volume":"78","author":"K Aabo","year":"1998","unstructured":"Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced ovarian Cancer Trialists\u2019 Group. Br J Cancer. 1998;78:1479\u201387.","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"1381_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1023\/A:1008355317514","volume":"10","author":"A du Bois","year":"1999","unstructured":"du Bois A, Neijt JP, Thigpen JT. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care? Ann Oncol. 1999;10(Suppl 1):35\u201341.","journal-title":"Ann Oncol"},{"key":"1381_CR9","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21:3194\u2013200.","journal-title":"J Clin Oncol"},{"key":"1381_CR10","first-page":"343","volume":"18","author":"RJ West","year":"1997","unstructured":"West RJ, Zweig SF. Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. Eur J Gynaecol Oncol. 1997;18:343\u20138.","journal-title":"Eur J Gynaecol Oncol"},{"key":"1381_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699\u2013708.","journal-title":"J Natl Cancer Inst"},{"key":"1381_CR12","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","volume":"18","author":"JP Neijt","year":"2000","unstructured":"Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18:3084\u201392.","journal-title":"J Clin Oncol"},{"key":"1381_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","volume":"18","author":"FM Muggia","year":"2000","unstructured":"Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian Cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18:106.","journal-title":"J Clin Oncol"},{"key":"1381_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian Cancer. N Engl J Med. 1996;334:1\u20136.","journal-title":"N Engl J Med"},{"key":"1381_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","volume":"360","author":"International Collaborative Ovarian Neoplasm Group","year":"2002","unstructured":"International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360:505\u201315.","journal-title":"Lancet"},{"key":"1381_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386:249\u201357.","journal-title":"Lancet"},{"key":"1381_CR17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian Cancer. N Engl J Med. 2010;363:943\u201353.","journal-title":"N Engl J Med"},{"key":"1381_CR18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3892\/or_00000479","volume":"22","author":"M P\u00f6lcher","year":"2009","unstructured":"P\u00f6lcher M, Mahner S, Ortmann O, et al. Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR). Oncol Rep. 2009;22:605\u201313.","journal-title":"Oncol Rep"},{"key":"1381_CR19","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396.","journal-title":"N Engl J Med"},{"key":"1381_CR20","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383.","journal-title":"N Engl J Med"},{"key":"1381_CR21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928\u201336.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"1381_CR22","doi-asserted-by":"publisher","first-page":"i40","DOI":"10.1093\/annonc\/mdw094","volume":"27","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA. PARP inhibitors in ovarian cancer. Ann Oncol. 2016;27(Suppl 1):i40\u20134.","journal-title":"Ann Oncol"},{"key":"1381_CR23","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1093\/annonc\/mdy174","volume":"29","author":"MR Mirza","year":"2018","unstructured":"Mirza MR, Pignata S, Ledermann JA. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann Oncol. 2018;29:1366\u201376.","journal-title":"Ann Oncol"},{"key":"1381_CR24","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer. N Engl J Med. 2018;379:2495\u2013505.","journal-title":"N Engl J Med"},{"key":"1381_CR25","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384.","journal-title":"Lancet Oncol"},{"key":"1381_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ygyno.2006.07.034","volume":"104","author":"T Petit","year":"2007","unstructured":"Petit T, Velten M, d\u2019Hombres A, et al. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy. Gynecol Oncol. 2007;104:104\u20138.","journal-title":"Gynecol Oncol"},{"key":"1381_CR27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0360-3016(99)00227-8","volume":"45","author":"R Wong","year":"1999","unstructured":"Wong R, Milosevic M, Sturgeon J, et al. Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: results of a prospective treatment protocol. Int J Radiat Oncol Biol Phys. 1999;45:657\u201365.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1381_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/0360-3016(92)90779-H","volume":"22","author":"TJ Whelan","year":"1992","unstructured":"Whelan TJ, Dembo AJ, Bush RS, et al. Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer. Int J Radiat Oncol Biol Phys. 1992;22:853\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1381_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/0090-8258(91)90250-9","volume":"41","author":"JA Ledermann","year":"1991","unstructured":"Ledermann JA, Dembo AJ, Sturgeon JF, et al. Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation. Gynecol Oncol. 1991;41:30\u20135.","journal-title":"Gynecol Oncol"},{"key":"1381_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1046\/j.1525-1438.2003.13193.x","volume":"13","author":"Sorbe B, Swedish-Norgewian Ovarian Cancer Study Group","year":"2003","unstructured":"Sorbe B, Swedish-Norgewian Ovarian Cancer Study Group. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer. 2003;13:278\u201386.","journal-title":"Int J Gynecol Cancer"},{"key":"1381_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0167-8140(99)00144-9","volume":"53","author":"N Einhorn","year":"1999","unstructured":"Einhorn N, Lundell M, Nilsson B, et al. Is there place for radiotherapy in the treatment of advanced ovarian cancer? Radiother Oncol. 1999;53:213\u20138.","journal-title":"Radiother Oncol"},{"key":"1381_CR32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/0360-3016(92)90778-G","volume":"22","author":"AW Fyles","year":"1992","unstructured":"Fyles AW, Dembo AJ, Bush RS, et al. Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma. Int J Radiat Oncol Biol Phys. 1992;22:847\u201351.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1381_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijrobp.2004.09.010","volume":"62","author":"R Dinniwell","year":"2005","unstructured":"Dinniwell R, Lock M, Pintilie M, et al. Consolidative abdominopelvic radiotherapy after surgery and carboplatin\/paclitaxel chemotherapy for epithelial ovarian cancer. Int J Radiat Oncol Biol Phys. 2005;62:104\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1381_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1006\/gyno.1998.5184","volume":"72","author":"H Pickel","year":"1999","unstructured":"Pickel H, Lahousen M, Petru E, et al. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian Cancer. Gynecol Oncol. 1999;72:215\u20139.","journal-title":"Gynecol Oncol"},{"key":"1381_CR35","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/S0360-3016(01)02785-7","volume":"52","author":"AJ Mundt","year":"2002","unstructured":"Mundt AJ, Lujan AE, Rotmensch J, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002;52:1330\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1381_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0167-8140(01)00473-X","volume":"62","author":"CW Hurkmans","year":"2002","unstructured":"Hurkmans CW, Cho BCJ, Damen E, et al. Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. Radiother Oncol. 2002;62:163\u201371.","journal-title":"Radiother Oncol"},{"key":"1381_CR37","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.ijrobp.2009.03.061","volume":"76","author":"N Rochet","year":"2010","unstructured":"Rochet N, Sterzing F, Jensen AD, et al. Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin\/Taxane chemotherapy for advanced ovarian Cancer: phase I study. Int J Radiat Oncol Biol Phys. 2010;76:1382\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1381_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-2407-11-41","volume":"11","author":"N Rochet","year":"2011","unstructured":"Rochet N, Kieser M, Sterzing F, et al. Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III - the OVAR-IMRT-02 study. BMC Cancer. 2011;11:41.","journal-title":"BMC Cancer"},{"key":"1381_CR39","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ijrobp.2017.06.2465","volume":"99","author":"N Arians","year":"2017","unstructured":"Arians N, Kieser M, Benner L, et al. Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): first results of a prospective phase 2 study. Int J Radiat Oncol Biol Phys. 2017;99:912\u201320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1381_CR40","volume-title":"A language and environment for statistical computing","author":"R Core team","year":"2018","unstructured":"R Core team. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. URL \n                    https:\/\/www.R-project.org\/"},{"key":"1381_CR41","doi-asserted-by":"publisher","first-page":"129s","DOI":"10.1200\/JCO.2003.04.003","volume":"21","author":"SA Cannistra","year":"2003","unstructured":"Cannistra SA, Bast RC, Berek JS, et al. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol. 2003;21:129s\u201332s.","journal-title":"J Clin Oncol"},{"key":"1381_CR42","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/ijgc-00009577-200409000-00006","volume":"14","author":"HE Lambert","year":"2004","unstructured":"Lambert HE, Gregory WM, Nelstrop AE, et al. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer. 2004;14:772\u20138.","journal-title":"Int J Gynecol Cancer"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1381-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-019-1381-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1381-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T23:22:17Z","timestamp":1603149737000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-019-1381-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1186\/s13014-019-1381-2","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]},"assertion":[{"value":"28 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local Ethics Committee of Heidelberg University. Written informed consent was obtained from each participant before entering the trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}